Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK-based drug discovery company, Summit's drug candidate, SMT C1100, used to treat Duchenne Muscular Dystrophy (DMD) has earned orphan drug status from the US FDA.
Subscribe to our email newsletter
The drug received orphan drug status by the European Medicines Agency (EMA) in December 2008.
SMT C1100 is a small molecule drug that increases (upregulating) production of a similar, naturally occurring protein called utrophin to replace the missing dystrophin.
Summit Executive Chairman Barry Price said the approval recognizes the drug’s efficacy in the treatment of DMD.
"Our clinical candidate has now been granted orphan drug status both in Europe and the US, and this status will provide additional regulatory support and various commercial benefits including extended periods of market exclusivity," Price added.